Master malignant bowel obstruction, cancer-associated thrombosis, and goals-of-care conversations in hospitalized patients with advanced cancer. Learn practical approaches to symptom management, anticoagulation decisions, and navigating high-stakes discussions around prognosis and hospice care. We’re joined by Dr. Jensa Morris, @JensaMorrisMD (Yale School of Medicine).
Claim free CME for this episode at curbsiders.vcuhealth.org!
Show Segments
Oncology Potpourri for the Hospitalist Pearls

Oncology Potpourri for the Hospitalist
Malignant Bowel Obstruction
Defining Malignant Bowel Obstruction
Malignant bowel obstruction (MBO) refers to a partial or complete obstruction of the bowel distal to the ligament of Treitz caused directly or indirectly by malignancy (Anthony, et al., 2007).
Compared with adhesive small bowel obstruction, which often presents more acutely in otherwise stable patients, malignant bowel obstruction is frequently a more subacute or progressive process associated with multifocal obstruction, ascites, cachexia, and ongoing cancer-related decline.
CT abdomen/pelvis with IV contrast is typically the preferred imaging modality because it helps confirm the obstruction, identify complications, and assess overall disease burden.
Dr. Morris emphasizes that MBO is often a marker of advanced disease and poor prognosis, particularly in patients with recurrent obstruction, multifocal disease, ascites, or declining performance status.
Initial Stabilization and Symptom Management
Initial management generally centers on IV fluids, antiemetics, bowel decompression when needed, and adequate opioid therapy for symptom relief.
Dr. Morris emphasizes that even during the initial stabilization of malignant bowel obstruction, clinicians should begin exploring the patient’s understanding of their illness and overall trajectory. Establishing this context early helps guide decisions about decompression, procedures, symptom management, and overall treatment intensity throughout the hospitalization.
NG Tubes, Antiemetics, Opioids, and Antisecretory Therapy
For symptom management, Dr. Morris emphasizes that antiemetic selection in malignant bowel obstruction differs somewhat from standard nausea management and shares that she frequently uses the National Comprehensive Cancer Network guidelines to help guide management decisions in these patients (NCCN Clinical Practice Guidelines in Oncology: Palliative Care Version 2.2026). In patients with partial obstruction, metoclopramide can be helpful because of its pro-motility effects, though she cautions that she uses it carefully since a partial obstruction may later progress to a complete obstruction. In patients with complete obstruction, she avoids pro-motility agents.
Dr. Morris notes that antisecretory therapy is often a cornerstone of pharmacological management in MBO. Her preferred agent is octreotide, which can reduce gastrointestinal secretions and vomiting and is typically administered subcutaneously or IV multiple times daily. Additional commonly used antiemetics include olanzapine and haloperidol.
Dr. Morris also notes that corticosteroids are sometimes used as adjunctive therapy in malignant bowel obstruction (Walter et al., 2024 and Feuer et al., 1999), despite limited high-quality evidence. Her practice is to trial dexamethasone (commonly 2–4 mg IV) for several days in select patients, which is also consistent with the NCCN guidelines.
If patients remain significantly symptomatic despite initial medical management—particularly those with severe nausea, vomiting, or abdominal distention—Dr. Morris may recommend temporary nasogastric tube decompression. She notes that some patients experience dramatic relief after removal of several liters of gastric contents, though her preference is generally to avoid leaving NG tubes in place long term whenever possible.
Procedural Management: Surgery, Stenting, and Venting G Tubes
While some patients may benefit from surgery or endoscopic stenting, many patients with advanced malignancy, multifocal obstruction, or extensive peritoneal carcinomatosis are poor procedural candidates and are managed primarily with symptom-directed therapy. In addition to survival, she highlights the importance of discussing the burden of recurrent admissions and time spent in the hospital versus at home, since many patients with recurrent malignant SBO spend a substantial portion of their remaining life hospitalized (Olson et al., 2014).
For patients with recurrent or refractory symptoms, venting gastrostomy tubes can provide substantial symptomatic relief and reduce recurrent hospitalizations. Patients may be able to clamp the tube and resume some oral intake when feeling well, then unclamp it during episodes of worsening nausea, vomiting, or distention. She emphasizes that this approach can help patients avoid repeated emergency department visits and prolonged hospital stays while improving overall quality of life (Zucchi et al., 2016).
Large-volume ascites can complicate venting G-tube placement because the stomach may not adequately appose the abdominal wall. In these situations, patients may require concurrent management of ascites—sometimes with placement of a tunneled peritoneal drain (e.g., Denver drain) at the same time as venting G-tube placement to facilitate the procedure and improve ongoing symptom control.
Nutrition, Hydration, and TPN in Malignant SBO
Dr. Morris notes that the NCCN palliative care guidelines generally discourage TPN when the underlying malignancy is expected to be the primary life-limiting process rather than starvation from the obstruction itself. However, she emphasizes that important exceptions exist. She describes select patients with more indolent malignancies who may have meaningful survival and quality-of-life benefit from long-term TPN in combination with supportive interventions like venting G tubes.
At the same time, Dr. Morris highlights that clinicians should recognize the overall literature does not demonstrate a consistent improvement in quality or quantity of life with TPN for most patients with advanced malignant bowel obstruction (Sowerbutts et al. 2018). These discussions should therefore remain individualized and grounded in prognosis, functional status, and the patient’s goals and priorities.
Cancer-Associated Venous Thromboembolism
Choosing Between DOACs and LMWH in Patients with Cancer
Dr. Morris explains that both direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) are appropriate options for treatment of cancer-associated venous thromboembolism in many patients with solid tumors. The NCCN guidelines generally favor LMWH in patients with gastric or gastroesophageal malignancies because of the increased risk of hemorrhage in these cancers (NCCN Guidelines Version 1.2026 Cancer-Associated Venous Thromboembolic Disease).
Additionally, considering the patient’s concurrent cancer therapies when managing anticoagulation is important. She specifically notes that vascular endothelial growth factor (VEGF) inhibitors such as bevacizumab can paradoxically increase the risk of both thrombosis and bleeding.
Duration of Anticoagulation in Active Malignancy
The general principle of anticoagulation in cancer-associated thrombosis is that patients typically remain anticoagulated for as long as the malignancy is active or cancer-directed therapy continues. In practice, this often means indefinite anticoagulation for patients with metastatic disease.
She also highlights emerging data supporting dose reduction strategies during the extended treatment phase. Specifically, after six months of full-dose anticoagulation, some patients with ongoing active cancer may transition from apixaban 5 mg twice daily to 2.5 mg twice daily, based on newer trial data demonstrating similar efficacy with lower bleeding risk during long-term therapy (API-CAT Trial: Mahé, et al., 2025). Dr. Morris notes that the clinical relevance of this strategy depends heavily on the patient’s prognosis and overall trajectory.
Incidental PE, Visceral Vein Thrombosis, and Tumor Thrombus
Incidental pulmonary emboli are extremely common in patients with cancer, often identified on routine staging or surveillance imaging. Unlike in the general medical population—where isolated incidental subsegmental PE may sometimes be managed conservatively—she emphasizes that cancer-associated thrombosis is approached more aggressively. Per Dr. Morris, “every clot in cancer is an important clot,” and incidental PE in patients with active malignancy is generally treated with therapeutic anticoagulation similarly to symptomatic VTE.
The same general principle extends to incidental splanchnic and mesenteric vein thrombosis in patients with active malignancy. In most cases, these thrombi are treated similarly to DVT or PE with therapeutic anticoagulation because cancer-associated clots are considered clinically meaningful even when asymptomatic.
Anticoagulation and Brain Metastases
Most patients with brain metastases can still receive therapeutic anticoagulation when clinically indicated, though certain malignancies warrant additional caution because of their higher risk of intracranial hemorrhage. Melanoma, renal cell carcinoma, thyroid cancer, and choriocarcinoma as malignancies with particularly increased risk of hemorrhagic brain metastases (Lin, et al., 2018) where multidisciplinary discussion is especially important before initiating therapeutic anticoagulation.
She also notes that the status of the brain metastases matters. Untreated brain metastases are generally more concerning for bleeding than previously treated lesions. For example, she describes feeling much more comfortable anticoagulating patients with treated brain metastases—such as lung cancer metastases managed with stereotactic radiosurgery—whereas newly discovered untreated metastases often prompt more careful interdisciplinary discussion.
Prognosis and Performance Status in Advanced Cancer
Palliative Care Consultation and Goals-of-Care Conversations
Dr. Morris strongly advocates for early palliative care involvement, emphasizing that consultation should occur “early and often” rather than waiting until the final stages of illness or transition to hospice. In patients with recurrent malignant bowel obstruction, progressive disease, repeated hospitalizations, and worsening functional decline, palliative care can provide substantial support with symptom management, prognostic discussions, communication, and discharge planning. She highlights that these conversations are ideally introduced well before a patient reaches the final days or weeks of life.
One of the major strengths of palliative care is expert symptom management. While hospitalists may be comfortable with first-line approaches to pain, nausea, and vomiting, palliative care often provides additional expertise for refractory symptoms and more advanced therapies such as ketamine infusions, PCA management, and complex multidrug antiemetic regimens.
Palliative care is also a collaborative partner in communication and goals-of-care discussions. Although hospitalists on her service routinely lead serious illness conversations, she notes that these discussions are often most effective when conducted alongside palliative care clinicians who can provide additional support for patients, families, and the primary team.
Dr. Morris acknowledges that some patients with advanced cancer and poor prognosis may still choose life-prolonging treatment despite extensive discussions about prognosis and hospice. She emphasizes that goals-of-care conversations should remain centered on the patient’s wishes rather than the clinician’s preferences, and that clinicians must respect these decisions unless clear ethical concerns exist.
Symptom Focused Management at End-of-Life
Dr. Morris acknowledges that transitions toward symptom-focused care and hospice can feel abrupt for patients and families, particularly when they were recently discussing additional cancer-directed treatment. She emphasizes the importance of explicitly recognizing this change in trajectory during conversations with patients.
She recommends using clear, empathetic language that connects the patient’s clinical decline to the underlying cancer progression. She sometimes shares that “patients in similar situations often make decisions like…” to help reduce the sense that the patient is facing an isolated or uniquely frightening choice. In her expert opinion, this framing can make discussions about hospice and comfort-focused care feel less overwhelming and more grounded in shared human experience.
Dr. Morris reflects on several communication pitfalls she has learned over time. One major mistake she cautions against is leading serious illness conversations by immediately discussing code status, which can prematurely narrow the discussion to resuscitation decisions before understanding the patient’s broader goals and priorities. Similarly, she tries to avoid framing conversations solely around a single intervention—such as surgery, TPN, or another escalation of care—because patients and families may understandably fixate on that individual decision rather than the overall clinical trajectory and bigger picture of what medical care is trying to accomplish.
Hospice and Discharge Planning
Dr. Morris emphasizes that successful hospice discharge planning requires careful coordination before the patient leaves the hospital. Her first priority is ensuring the patient is formally enrolled in hospice and that hospice services will evaluate the patient within 24 hours of discharge to help avoid unwanted return visits to the emergency department.
She also stresses the importance of arranging all necessary durable medical equipment (DME) and home supplies in advance, including hospital beds and any equipment related to symptom management such as venting G-tube supplies. Family education is equally important so caregivers feel prepared to manage medications, drains, tubes, and expected symptom changes at home.
Links
Nashville Themed Picks of the Week:
Goal
Listeners will develop a practical approach to the hospitalized patient with malignant bowel obstruction and cancer-associated venous thromboembolism while incorporating prognosis and goals-of-care discussions.
Learning objectives
After listening to this episode listeners will…
Disclosures
Dr. Morris reports no relevant financial disclosures. The Curbsiders report no relevant financial disclosures.
Citation
Blackburn, R., Morris, J., Trubitt M, Amin M, Coleman C, Williams PN, Watto MF. “527 Oncology Potpourri for the Hospitalast”. The Curbsiders Internal Medicine Podcast. thecurbsiders.com/category/curbsiders-podcast Final publishing date June 1, 2026.
Visit CMEmeeting.org/curbsiders and use promo code Curb30 for 30% off all online courses and webcasts.
Locumstory.com is literally just a free, unbiased resource dedicated to educating physicians about locums.
To get your new wireless plan for just 15 bucks a month, go to mintmobile.com/CURB.
Writer, producer, and show notes: Reaford Blackburn, Jr., MD
Infographic, Cover Art: Caroline Coleman, MD
Hosts: Monee Amin, MD and Meredith Trubitt, MD
Reviewer: Rahul Ganatra, MD
Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP
Technical Production: PodPaste
Guest: Jensa Morris, MD
The Curbsiders are partnering with VCU Health Continuing Education to offer continuing education credits for physicians and other healthcare professionals. Visit ce.vcuhealth.org/curbsiders and search for this episode to claim credit.
Got feedback? Suggest a Curbsiders topic. Recommend a guest. Tell us what you think.
We love hearing from you.

Yes, you can now join our exclusive community of core faculty at Kashlak Memorial Hospital along with all the perks:
Notice
We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes as specified in the cookie policy. Denying consent may make related features unavailable.
Close this notice to consent.